Teva last week settled a patent lawsuit with Aurobindo for its generic challenger to Austedo, Teva’s VMAT2 inhibitor. Under the terms of the settlement, the generic cannot launch until April 2033. Austedo is the only VMAT2 inhibitor approved for the treatment of tardive dyskinesia, an indication for which it holds covered or better status for 96% of all insured lives under the pharmacy benefit. About 44% of insured lives have preferred access to Austedo, largely with utilization management restrictions applied. The drug is also approved for the treatment of chorea associated with Huntington’s disease.
SOURCE: MMIT Analytics, as of 6/13/22